Jarosław Leszczyszyn

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

Bruce E. Sands, Peter M. Irving, Timothy Hoops et al. · The Lancet · 2022 · 277 citations

Immunology, Clinical Trials, Gastroenterology +7

Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease

Stefan Schreiber, Shomron Ben‐Horin, Jarosław Leszczyszyn et al. · Gastroenterology · 2021 · 216 citations

Inflammation, Anti-inflammatory, Controlled Trial +5

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan, Bruce E. Sands, William J. Sandborn et al. · ˜The œLancet. Gastroenterology & hepatology · 2023 · 208 citations

Systemic Treatment, Golimumab Monotherapy, Gastroenterology +4

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 86 citations · Full text

Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study

William J. Sandborn, Silvio Danese, Jarosław Leszczyszyn et al. · Clinical Gastroenterology and Hepatology · 2023 · 82 citations

Gastrointestinal Pharmacology, Phase 2B, Moderate-to-severe Ulcerative Colitis +5